Search results
QDEL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that QuidelOrtho Investors with...
Benzinga· 2 days agoAttorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against QuidelOrtho ("QuidelOrtho" ...
Governor reiterates desire for full financial support of West Virginians with disabilities - WV...
WV MetroNews· 6 days agoState officials acknowledged this week that in recent years West Virginia spent millions of dollars...
DEADLINE ALERT for VFS, QDEL, and ASTS: The Law Offices of Frank R. Cruz Reminds Investors of Class...
Morningstar· 5 days agoThe Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines ...
Roche 1Q Sales CHF14.40B
Market Watch· 5 hours agoBy Helena Smolak Roche first-quarter sales declined amid weak demand for Covid-19 products and currency headwinds but slightly beat analysts expectations....
Unlocking Q1 Potential of Quest Diagnostics (DGX): Exploring Wall Street Estimates for Key Metrics
Zacks via Yahoo Finance· 2 days agoLooking beyond Wall Street's top -and-bottom-line estimate forecasts for Quest Diagnostics (DGX),...
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages QuidelOrtho Corporation Investors to Secure Counsel...
Digital Journal· 10 hours agoWHY: NEW YORK, NY - (NewMediaWire) - April 23, 2024 - Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of QuidelOrtho Corporation (NASDAQ: QDEL) between ...
Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities...
NBC 17 Raleigh· 5 days agoUpcoming Lead Plaintiff Deadline is June 11, 2024 NEW YORK, April 19, 2024 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf Haldenstein") announces that a federal securities ...
COVID-19 and PREP Act Immunity
The National Law Review· 6 days agoIn the wake of rising COVID-19 infections, many private companies have donated goods and services, developed testing and diagnostic tests, provided COVID-19 testing support to state and federal ...
Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges
FOX 5 San Diego· 7 days agoAbbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024. First-quarter GAAP diluted EPS of $0.70 and adjusted diluted EPS of $0.98, which excludes specified ...
UPDATE: Abbott Diagnostics Q1 Revenues Down 18 Percent, Total Revenues up 2 Percent
GenomeWeb News· 7 days agoAbbott on Wednesday announced that its Q1 2024 Diagnostics revenues declined 18 percent year over year as a result of declining COVID-19 testing sales. For the three months ended March 31, Abbott ...
